NCT05552846 is a NA clinical trial of thoracic radiotherapy in Small-cell Lung Cancer, sponsored by Ruijin Hospital.

Who is sponsoring NCT05552846?

NCT05552846 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT05552846?

Interventions in NCT05552846: thoracic radiotherapy.

What condition does NCT05552846 study?

NCT05552846 studies Small-cell Lung Cancer.

Is NCT05552846 still recruiting?

NCT05552846 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05552846

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

Recruiting now NA Last updated 19 September 2024

What this trial tests

NA trial testing thoracic radiotherapy in Small-cell Lung Cancer in 104 participants. Currently enrolling.

Timeline

30 January 2021

Primary endpoint
30 September 2025

30 September 2026

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	104
Start date	30 January 2021
Primary completion	30 September 2025
Estimated completion	30 September 2026
Sites	1 location across China

Drugs / interventions tested

thoracic radiotherapy

Conditions studied

Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 80, any sex, with Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations.
Chi X, Dong Y, Zhu L, Su D, et al · · 2025 · PMID 41415276 · DOI 10.3389/fimmu.2025.1693401
Advancements in consolidative thoracic radiotherapy following first-line immunotherapy in conjunction with chemotherapy for extensive-stage small cell lung cancer.
Liu J, Liu J, Chen D, Zhu Y, et al · · 2025 · PMID 41256848 · DOI 10.3389/fimmu.2025.1665072

Verify or expand the search:

Other trials of thoracic radiotherapy

Trials testing the same drug.

NCT06187740 — Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy · Phase 1 · unknown
NCT05298423 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizuma · Phase 3 · active not recruiting

Other recruiting trials for Small-cell Lung Cancer

Currently open trials in the same condition.

NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT · Phase 3 · recruiting
NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi · Phase 3 · recruiting
NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers · Phase 2 · recruiting
NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab · NA · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05552846 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05552846.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing